Investment analysts at HC Wainwright issued their Q2 2026 earnings per share estimates for shares of Rhythm Pharmaceuticals in a research note issued on Monday, March 24th. HC Wainwright analyst R.

We recently published a list of 10 Worst High-Risk High-Reward Growth Stocks To Buy. In this article, we are going to take a ...

Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $69.89, with a ...

Rhythm Pharmaceuticals (NASDAQ:RYTM – Free Report) had its target price increased by Needham & Company LLC from $64.00 to $66 ...

Rhythm Pharmaceuticals (RYTM) announced that it reacquired the rights to Imcivree in China, including mainland China, Hong Kong and Macau, as ...

Investors in Rhythm Pharmaceuticals Inc (Symbol: RYTM) saw new options begin trading today, for the May 16th expiration. One of the key inputs that goes into the price an option buyer is willing ...

Yann Mazabraud, the EVP of $RYTM, sold 55,803 shares of the company on 03-14-2025 for an estimated $2,886,226. We received data on the trade from a recent SEC filing ...

Rhythm Pharmaceuticals (RYTM) announced it has received orphan drug designation from Japan’s Ministry of Health, Labour and Welfare for ...

Over the last 7 days, the United States market has dropped 3.1%, yet it remains up by 13% over the past year with earnings anticipated to grow by 14% per annum in the coming years. In this dynamic ...